retatrutide triple agonist glp-1 gip glucagon phase 2 obesity Dr Eli Lilly's retatrutide shows promising
Description
[DOI] [PMC free article] [PubMed] [Google Scholar] 172.Traub S., Meier D.T., Schulze F., Dror E., Nordmann T.M., Goetz N
There is no benefit to reaching target dose faster if cardiovascular side effects become limiting
Jensterle M, Ferjan S, Leai L, et al
[DOI] [PubMed] [Google Scholar] 218.Seifarth C., Bergmann J., Holst J.J., Ritzel R., Schmiegel W., Nauck M.A
The starting dose is 0.1 mg (50 l) three times daily and is injected subcutaneously 5 minutes before meals
This provides a complete way to deal with fat and metabolic diseases
